Depends on the partnering route taken as to what the funds from the upfront are used for. The way I understand it:
Option A = Out license to big pharma = sale of the AD214 asset with an upfront payment & contingent milestones = no further spend on AD214 for Adalta, can use the upfront to develop the pipeline of other drugs
Option B = JV Partner with Private equity = AD214 into SPV, JV partner pays Adalta for a portion of equity in SPV = in phase II either the costs are shared with the JV partner or the JV partner pays 100% (depending on the deal and how much equity is given away) with hope of selling for more (to big pharma) at some point
- Forums
- ASX - By Stock
- 1AD
- Ann: Positive AD-214 Phase I extension study results
Ann: Positive AD-214 Phase I extension study results, page-203
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add 1AD (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.8¢ |
Change
-0.001(2.70%) |
Mkt cap ! $10.91M |
Open | High | Low | Value | Volume |
1.8¢ | 1.8¢ | 1.8¢ | $74 | 4.087K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 70421 | 1.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.9¢ | 197631 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 70421 | 0.018 |
2 | 1058823 | 0.017 |
7 | 968104 | 0.016 |
4 | 1659994 | 0.015 |
1 | 75000 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.019 | 197631 | 1 |
0.020 | 250000 | 1 |
0.021 | 372500 | 2 |
0.022 | 500000 | 1 |
0.023 | 17643 | 1 |
Last trade - 13.40pm 07/10/2024 (20 minute delay) ? |
Featured News
1AD (ASX) Chart |